Skip to main content

Edarbi FDA Approval History

FDA Approved: Yes (First approved February 25, 2011)
Brand name: Edarbi
Generic name: azilsartan medoxomil
Dosage form: Tablets
Company: Azurity Pharmaceuticals, Inc.
Treatment for: High Blood Pressure

Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.

Development timeline for Edarbi

Feb 28, 2011Approval FDA Approves Edarbi to Treat High Blood Pressure
Apr 27, 2010Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.